191 listed pharmaceutical companies announced their results, with 3 having a net profit of more than 2 billion yuan

[pharmaceutical network industry news] it is reported that by the end of last week, 191 of 317 pharmaceutical listed companies had released the 2019 performance forecast In general, the upper limit of net profit of 191 pharmaceutical listed companies making performance forecast is 34.944 billion yuan, and the lower limit of net profit is 25.070 billion yuan, with an average of 30.007 billion yuan It is worth noting that in the ranking of the predicted net profit, the top three enterprises have estimated net profit of more than 2 billion yuan Mindray medical: on January 20, Mindray medical released the 2019 performance forecast It is estimated that in 2019, it will achieve revenue of 15.816-17.192 billion, net profit of 4.463-4.835 billion and net profit of 4.397-4.769 billion, with year-on-year growth of 15-25%, 20-30% and 20-30% respectively The performance meets the market expectation Among many listed medical enterprises, the rising momentum of Mindray medical is quite rapid Since 2019, Mindray has been expanding its business scale and increasing its brand influence Its main business is life information and support, three cornerstone production lines of medical imaging and in vitro diagnosis, constantly improving its market share and realizing the rapid growth of high-end products and emerging businesses At present, Mindray medical has branches in more than 30 provinces and autonomous regions in China, and 40 overseas subsidiaries in more than 30 countries in North America, Europe, Asia, Africa, Latin America and other regions It is one of the few companies that competes positively with foreign medical giants Zhifei biology: on January 3, Zhifei biology issued the performance forecast It is estimated that in 2019, the net profit attributable to the shareholders of the listed company will be 2.250-2.540 billion yuan, an increase of 55% - 75% over the same period of last year In this regard, Zhifei Bio said that in 2019, the company continued to focus on the research and development, production, sales, promotion, distribution and import vaccine agent of vaccines and biological products, with steady progress in various works and smooth progress in product sales As a result, Zhifei biology has well completed the production and operation plan of 2019, and the main business income, net profit and other important financial indicators of listed companies have a good growth compared with the same period of last year In fact, since the "rocket speed" of the four price HPV vaccine and the nine price HPV vaccine entered China, as the mainland agent of these two heavyweight products, the performance of Zhifei biology has ushered in a blowout, and the prospect is very promising Several securities companies have analyzed and speculated that HPV vaccine series may contribute 1.7-1.9 billion yuan of net profit to Zhifei biology, accounting for 70% or more China Resources 39: as early as October 2019, the lower limit of predicted net profit was 21.1 billion yuan China Resources 39 announced the 2019 performance forecast Its performance is expected to show that in 2019, the profit attributable to the shareholders of the listed company is 2.11-2.25 billion yuan, and the net profit is 1432.08 million yuan, an increase of 47.34% - 57.11% over the same period of last year According to China Resources Sanjiu, the main reason for the substantial growth of its performance is that the company completed the sale of 82.89% of its shares in Shenzhen Sanjiu hospital Co., Ltd through public listing transfer in January 2019, bringing the company about 680 million yuan (after tax) asset disposal income, which is non recurring profit and loss.